35,664 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Nuance Investments LLC

Nuance Investments LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 35,664 shares of the medical research company’s stock, valued at approximately $17,880,000. Thermo Fisher Scientific accounts for 3.0% of Nuance Investments LLC’s portfolio, making the stock its 10th biggest holding.

A number of other institutional investors have also made changes to their positions in TMO. Salomon & Ludwin LLC grew its holdings in Thermo Fisher Scientific by 1.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock valued at $669,000 after purchasing an additional 17 shares in the last quarter. Elyxium Wealth LLC lifted its holdings in Thermo Fisher Scientific by 1.9% in the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock worth $613,000 after buying an additional 20 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. grew its stake in shares of Thermo Fisher Scientific by 0.7% during the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after acquiring an additional 20 shares in the last quarter. Finally, Confluence Wealth Services Inc. lifted its stake in shares of Thermo Fisher Scientific by 0.5% in the fourth quarter. Confluence Wealth Services Inc. now owns 4,292 shares of the medical research company’s stock worth $2,487,000 after acquiring an additional 22 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 0.8%

Thermo Fisher Scientific stock opened at $590.00 on Wednesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The firm’s 50-day moving average is $533.64 and its 200-day moving average is $508.36. The company has a market cap of $218.15 billion, a P/E ratio of 31.74, a PEG ratio of 2.39 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the sale, the vice president owned 14,784 shares of the company’s stock, valued at $8,574,720. The trade was a 28.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $71,191,194.75. The trade was a 7.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 52,053 shares of company stock valued at $30,643,589. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TMO shares. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Barclays increased their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Piper Sandler lifted their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Finally, Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.